---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-002185"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:23:39.767774+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics appoints COO Jeet Mahal as CEO; Ron Martell steps down, Thomas Wiggans named Executive Chair

## Summary
- Effective Jan 5, 2026, Jeet Mahal becomes CEO and President; he also joins the Board as Class III director.
- Outgoing CEO Ron Martell's departure is without cause; he receives 18 months base salary plus COBRA for up to 18 months.
- Thomas Wiggans, current Board Chair, appointed Executive Chair effective Jan 5, 2026.
- Mahal's annual salary increased to $600,000 with eligibility for performance bonus up to 50% of base salary.
- Company to host investor webinar on Jan 8, 2026 to present updated data from BEACON study and open-label extension in CSU/CIndU.

## SEC filing metadata
- accession: 0001213900-26-002185
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390026002185/0001213900-26-002185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390026002185/ea0271735-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-002185
- JSON: https://secwatch.observer/filing/0001213900-26-002185.json
- Plain text: https://secwatch.observer/filing/0001213900-26-002185.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.